Close Menu


If It's Really Good

Late-stage vaccine trials could be stopped early if the data coming out of them is overwhelmingly positive, the Los Angeles Times reports.

The US National Institutes of Health is establishing the Centers for Research in Emerging Infectious Diseases to study pathogen spillover.

CNN reports the change in the US Centers for Disease Control and Prevention's coronavirus testing guidelines was in response to administration pressure.

A Rush on It?

The Financial Times reports the Trump Administration is exploring an Emergency Use Authorization for a coronavirus vaccine for October.

Phase III Begins

NPR reports Moderna has begun Phase III testing of its candidate SARS-CoV-2 vaccine.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

Going or Staying

President Donald Trump said Tuesday the US coronavirus task force would be winding down, but then reversed himself Wednesday, saying it would continue its work indefinitely, CNBC reports.

Early trials give conflicting results on remdesivir to treat COVID-19, though a large trial suggests it shortens disease length, Nature News reports.

Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.

Healthy adults from across the US with no confirmed history of COVID-19 and no current symptoms are eligible to participate and will be enrolled over the phone.


The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.

A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.

NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.

In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.